Last reviewed 2026-06-02 · How we verify

Basiliximab treatment

Basiliximab treatment is a Monoclonal antibody; IL-2 receptor antagonist Small molecule drug developed by Nantes University Hospital. It is currently FDA-approved for Prevention of acute organ rejection in adult and pediatric patients receiving renal transplants (as part of an immunosuppressive regimen).

Basiliximab is a chimeric monoclonal antibody that blocks the interleukin-2 (IL-2) receptor on T cells, preventing T cell activation and proliferation.

Basiliximab is used to treat conditions such as kidney transplantation and various types of leukemia, including acute myelogenous leukemia, acute lymphocytic leukemia, and chronic myelogenous leukemia. It is administered as part of an immunosuppressive regimen, often in combination with other treatments like belatacept, anti-thymocyte globulin, and methylprednisolone.

At a glance

Mechanism of action

Basiliximab binds specifically to the alpha chain (CD25) of the IL-2 receptor on activated T lymphocytes. By blocking IL-2 signaling, it inhibits T cell proliferation and differentiation, thereby suppressing the immune response responsible for organ rejection. This selective targeting of activated T cells makes it useful as an induction immunosuppressant in transplantation.

Approved indications

• Prevention of acute organ rejection in adult and pediatric patients receiving renal transplants (as part of an immunosuppressive regimen)

Common side effects

• Infection
• Hypertension
• Tremor
• Headache
• Constipation
• Diarrhea
• Nausea

Key clinical trials

• Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
• Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients (PHASE4)
• Simulect Versus ATG in Sensitized Renal Transplant Patient (PHASE4)
• Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (PHASE2)
• Stem Cell Transplantation for Patients With Multiple Myeloma (PHASE1)
• 1 vs 7 RATG Infusions in Renal Transplantation
• Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL (PHASE2, PHASE3)
• 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Basiliximab treatment CI brief — competitive landscape report
• Basiliximab treatment updates RSS · CI watch RSS
• Nantes University Hospital portfolio CI

Frequently asked questions about Basiliximab treatment

Related

• Drug class: All Monoclonal antibody; IL-2 receptor antagonist drugs
• Target: All drugs targeting CD25 (IL-2 receptor alpha chain)
• Manufacturer: Nantes University Hospital — full pipeline
• Therapeutic area: All drugs in Immunology; Transplantation
• Indication: Drugs for Prevention of acute organ rejection in adult and pediatric patients receiving renal transplants (as part of an immunosuppressive regimen)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing